anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
PROBLEM TO BE SOLVED: To provide a pharmacy supporting system for supporting the sale processing of medicine or the issue of a receipt based on a prescription mainly for a medicine preparing pharmacy. SOLUTION: When a customer brings a prescription 5 to a pharmacy 1 in order to request medicine preparation, the pharmacy 1 inputs the contents of the prescription 5 to terminal equipment 6. The contents are transmitted via a network 4 to a host computer 3 as prescription information 11. The host computer 3 processes the prescription information 11 by a medicine sale processing supporting means 7. The terminal equipment 6 of the pharmacy 1 generates the image of a delivery slip or receipt related with the prescribed medicine according to information 13 for selling medicine returned to the terminal equipment 6. While the price of medicine is extremely frequency revised, it is always updated to the latest one at the host computer 3 side so that it is possible to always sell the medicine at the latest price of medicine.  Also, a service providing side only allows the host computer to update the price of medicine.
<P>PROBLEM TO BE SOLVED: To provide a method for deciding whether or not a DNA sequence includes characteristics of regulating gene transcription and/or characteristics of suppressing the gene transcription.  <P>SOLUTION: The method for detecting and optionally selecting the DNA sequence having the characteristics of regulating the gene transcription and includes preparing a vector comprising various fragments in a transcription system. The vector includes: (i) an element having characteristics of suppressing the gene transcription; and (ii) a promoter directing the transcription of a reporter gene. The method further includes performing a selection step in the transcription system in order to identify the DNA sequence having the characteristics of regulating the gene transcription. Furthermore, there is provided a method for use thereof in various fields such as, but not limited to protein production, diagnostics, transgenic plants and animals, and the therapeutic field.  <P>COPYRIGHT: (C)2010,JPO&INPIT
The study will begin at Dose Level 1 at 480 mg/m2 Nelarabine (75% of single agent maximum tolerated dose) and 330 mg/m2 Cyclophospamide and will escalate to the next Dose Level if the maximum tolerated dose (MTD) is not exceeded. The first 3 patients will be enrolled into Dose Level 1. If 0/3 experiences dose limiting toxicity (DLT) at a given dose level, then the dose is escalated to the next higher level and 3 more patients are enrolled. If 1/3 experiences DLT at current dose, the up to 3 more patients are accrued at the same dose level. If 2 or more DLTs are observed in a 3-patient or 6-patient cohort at a given dose level, then the MTD has been exceeded, dose escalation will be stopped, and up to 3 additional patients will be enrolled at the next lower dose level (unless 6 patients have already been treated at that prior dose). If the MTD is exceeded at Dose Level 0, the study will be closed.
FIELD: medicine, pharmacy. SUBSTANCE: invention relates to making nebivolol-containing drugs. Pharmaceutical composition has a carrier and an active component - nebivolol or its pharmaceutically acceptable salt being an active component is prepared as a micronized solid form. Micronized form of nebivolol hydrochloride has specific surface 23 x 10 3  cm 2 /g, not less. Pharmaceutical composition can be made as a tablet that is dissolved in 45 min by 75%. Invention ensures to obtain nebivolol-containing drugs exhibiting the enhanced bioavailability and dissolving rate of an active substance in gastric fluid. Solubility of micronized nebivolol and its salts was worse as compared with its an usual crystalline form but solubility of an active component to obtain pharmaceutical compositions containing additional agents corresponds to requirements. Early nebivolol and its salts could not be used orally due to its poor solubility. EFFECT: improved quality and properties of compositions. 10 cl, 6 ex
During long-term follow-up heart transplant recipients are at risk of developing different complications that are likely to affect quality of life and survival. The most common cause of death during the later stages after heart transplantation is cardiac allograft vasculopathy, followed by unexplained graft dysfunction. In this study, advanced imaging techniques will be used to describe the frequency of these two complications, examine possible risk factors and study consequences on functional capacity and quality of life. Further, the investigators will investigate whether it is feasible to screen for these conditions with non-invasive imaging methods. By studying patients that have performed cardiac transplantation between 10 and 20 years ago, the investigators expect to have a significant proportion of patients with these pathological conditions. Methods that will be used include cardiac magnetic resonance imaging, coronary flow velocity reserve assessment, right heart catheterization and coronary imaging with angiography and optical coherence tomography.
Loss of S-methyl-5'-thioadenosine phosphorylase (MTAP) expression is a common event in cancer leading to a critical vulnerability of cancer cells towards anti-cancer drugs. Homozygous MTAP deletions result in a complete expression loss that can be detected by immunohistochemistry (IHC). In this study, a tissue microarray containing 17,078 samples from 149 different tumor entities was analyzed by IHC, and complete MTAP loss was validated by fluorescence in situ hybridization. MTAP loss was observed in 83 of 149 tumor categories, including neuroendocrine neoplasms (up to 80%), Hodgkin lymphoma (50.0%), mesothelioma (32.0% to 36.8%), gastro-intestinal adenocarcinoma (4.0% to 40.5%), urothelial neoplasms (10.5% to 36.7%), squamous cell carcinomas (up to 38%), and various types of sarcomas (up to 20%) and non-Hodgkin lymphomas (up to 14%). Homozygous MTAP deletion was found in 90% to 100% of cases with MTAP expression loss in most tumor categories. However, neuroendocrine tumors, Hodgkin lymphomas, and other lymphomas lacked MTAP deletions. MTAP deficiency was significantly linked to unfavorable tumor phenotype in selected tumor entities and the presence of PD-L1 expression on tumor cells, absence of PD-L1 expression on immune cells, and a low density of CD8 + lymphocytes. In summary, MTAP deficiency can occur in various tumor entities and is linked to unfavorable tumor phenotype and noninflamed tumor microenvironment, but is not always related to deletions. MTAP IHC is of considerable diagnostic value for the detection of neoplastic transformation in multiple different applications.
Participants will receive golimumab 50 milligram (mg) subcutaneous (SC) injection at Week 0 and every 4 weeks (q4w) thereafter through Week 24. Concomitant medications may be allowed on a case by case basis as per the physician's judgement.
Participants will receive an intravenous (IV) infusion of Toripalimab 240mg on Day 1, Albumin-bound Paclitaxel 125mg/m\^2 on Days 1 and 8, Carboplatin with an area under the curve (AUC) of 5 on Day 1, and Cetuximab 400mg/m\^2 on Day 1, followed by Cetuximab 250mg/m\^2 on Day 1 of each subsequent week. The treatment is given in 21-day cycles for a total of two cycles. Afterward, participants will proceed to the standard of care (SOC), which includes surgical intervention and postoperative radiotherapy. Following surgical resection, high-risk participants will receive standard radiotherapy plus Cisplatin 100 mg/m\^2 via intravenous infusion on Day 1, every 3 weeks (Q3W) for three 21-day cycles. Low-risk participants will receive only standard radiotherapy. Subsequently, participants will receive Toripalimab 240mg every 21-day cycle for a total of 15 cycles.
The cysteinyl leukotrienes (LTC 4, LTD 4, LTE 4) are products of arachidonic acid metabolism and are released from various cells, including mast cells and eosinophils. These eicosanoids bind to cysteinyl leukotriene (CysLT) receptors. The CysLT type-1 (CysLT1) receptor is found in the human airway (including airway smooth muscle cells and airway macrophages) and on other pro-inflammatory cells (including eosinophils and certain myeloid stem cells). CysLTs have been correlated with the pathophysiology of asthma and allergic rhinitis. In asthma, leukotriene-mediated effects include airway edema, smooth muscle contraction, and altered cellular activity associated with the inflammatory process. In allergic rhinitis, CysLTs are released from the nasal mucosa after allergen exposure during both early- and late-phase reactions and are associated with symptoms of allergic rhinitis.   
Montelukast is an orally active compound that binds with high affinity and selectivity to the CysLT1 receptor (in preference to other pharmacologically important airway receptors, such as the prostanoid, cholinergic, or β-adrenergic receptor). Montelukast inhibits physiologic actions of LTD 4 at the CysLT 1 receptor without any agonist activity.
Safety and effectiveness of Desonide Gel, 0.05% in pediatric patients less than 3 months of age have not been evaluated, and therefore its use in this age group is not recommended.

The effect of Desonide Gel, 0.05% on HPA axis function was investigated in pediatric subjects, with atopic dermatitis covering at least 35% of their body, who were treated with Desonide Gel, 0.05% twice daily for 4 weeks. One of 37 subjects (3%) displayed adrenal suppression after 4 weeks of use, based on the cosyntropin stimulation test [see Warnings and Precautions (5.1)]. 

In controlled clinical studies in subjects 3 months to 18 years of age, 425 subjects were treated with Desonide Gel, 0.05% and 157 subjects were treated with vehicle [see Adverse Reactions (6) and Clinical Studies (14)]. 

Because of a higher ratio of skin surface area to body mass, pediatric patients are at a greater risk than adults of HPA axis suppression when they are treated with topical corticosteroids. They are therefore also at greater risk of glucocorticosteroid insufficiency after withdrawal of treatment and of Cushing’s syndrome while on treatment.

Adverse effects, including striae, have been reported with inappropriate use of topical corticosteroids in infants and children. HPA axis suppression, Cushing’s syndrome, linear growth retardation, delayed weight gain and intracranial hypertension have been reported in children receiving topical corticosteroids. Manifestations of adrenal suppression in children include low plasma cortisol levels and absence of response to ACTH stimulation. Manifestations of intracranial hypertension include bulging fontanelles, headaches, and bilateral papilledema.
An attenuated live measles virus vaccine is prepared by serially culturing a measles virus, that has been adapted to grow in living non-human cells, in a culture medium comprising living non-human animal cells at a temperature below 35 DEG C, but at a temperature higher than that at which propagation of the virus ceases.  The temperature is preferably 28 to 32 DEG C, for part or whole of the cultivation steps.  At least 40 serial passages are required. Avian particularly thick embryo tissue is preferred, but bovine kidney tissue may be used.  The measles virus may be an adapted strain of the Edmonston strain of measles virus e.g. Enders strain.  The strain employed may have been adapted to grow in living non-human cells by serial culture in (a) human e.g. amnion or heart tissue culture and then (b) animal tissue e.g. chick embryo tissue at conventional incubation temperatures e.g. 35 DEG C.  The culture fluid may be Earle's basic salt solution containing 5% calf serum or 10% of horse or lamb serum and 0.5% lactalbumin hydrolipate; or medium 199 with 5 or 10% of horse serum.  The separated virus may be stabilized with lactose glutamate solution and the final vaccine contains a parenterally acceptable diluent or is freeze-dried.  Reference has been directed by the Comptroller to Specification 968,980.
A wireless network includes Access Points (APs) that enable roaming by way of wireless devices switching between APs. A handover event within an analysis time interval is extracted from a wireless network log of the wireless network. Each handover event includes a source AP from which the wireless device is disconnected and a destination AP to which the wireless device is connected. At least one switching frequency (HF) network topology map for the analysis time interval is constructed from the extracted switching events. The graph has nodes representing at least a subset of the APs of the extracted handover event and edges connecting pairs of nodes, wherein the weight of each edge represents the count or frequency of handover events between the APs represented by the pair of nodes connected by the edge. Network diagnostics or visualization tasks are performed using the HF network topology map.
Alemtuzumab 30 mg/day is given subcutaneously on day 1-3 of cycle 1-5. CHOP alternate with ESHAP is given every 21 days for a total of 6 course.
The scientists will investigate the potential consequences of increasing baseline systolic blood pressure with intravenous fluids and phenylephrine by 20% to at least 160 mmHg until blood vessel recanalization is achieved or the thrombectomy procedure is completed. The maximum allowed SBP is 220 mmHg or 180 mmHg, if intravenous TPA was administered.
Motivational counseling supported by health technology (MOT) contains four individual and three group counseling sessions taking place from randomization until GA week 33+6 and aim to motivate the participants to increase their physical activity level at moderate intensity. During individual sessions, feedback on physical activity performance will be provided based on activity data acquired from the activity tracker and further, MOT-participants will receive weekly SMS-reminders about physical activity.
Glaucoma is an eye disease that leads to damage of the optic nerve, visual field loss and can progress to blindness. Traditionally, glaucoma and its treatment have been closely linked to intraocular pressures. In normal tension glaucoma, damage to the optic nerve occurs without any increase in intraocular pressure. Normal tension glaucoma most often occurs in the elderly and can lead to loss of sight and significant disability. Subjects with progressive visual field loss are often a highly motivated group of subjects, ready to take an active part in the treatment of their condition. Investigating the risk factors that contribute to the development of normal-tension glaucoma may shed light on the progression of the disease.

Subjects with normal tension glaucoma will have their demographic and clinical characteristics recorded and their eyes examined at baseline, 6-months and 12 months. Subjects will wear an external blood pressure cuff for 48 hours that will record blood pressure every 30 minutes. This same blood pressure recording procedure will be performed at baseline, at 6 months, and at 12 months. At these same time intervals, visual fields will also be measured, as per routine clinical care, by the treating ophthalmologist. The results of the visual field testing will be recorded. The primary outcome of the study will be visual field abnormalities and their relationship to dips in systemic blood pressure. Results will be published and will be used as a base for future projects that may impact treatment and the understanding of risk factors of normal tension glaucoma.
BACKGROUND: The intestinal microbiome is involved in the pathogenesis of chronic kidney disease (CKD). Despite its importance, the microbiome of the small intestinal mucosa has been little studied due to sampling difficulties, and previous studies have mainly focused on fecal sources for microbiome studies. We aimed to characterize the small intestinal microbiome of CKD patients by studying the microbiome collected from duodenal and fecal samples of CKD patients and healthy controls.
METHODS: Overall, 28 stage 5 CKD patients and 21 healthy participants were enrolled. Mucosal samples were collected from the deep duodenum during esophagogastroduodenoscopy and fecal samples were also collected. The 16S ribosomal RNA gene sequencing using Qiime2 was used to investigate and compare the microbial structure and metagenomic function of the duodenal and fecal microbiomes.
RESULTS: The duodenal flora of CKD patients had decreased alpha diversity compared with the control group. On the basis of taxonomic composition, Veillonella and Prevotella were significantly reduced in the duodenal flora of CKD patients. The tyrosine and tryptophan metabolic pathways were enhanced in the urea toxin-related metabolic pathways based on the Kyoto Encyclopedia of Genes and Genomes database.
CONCLUSION: The small intestinal microbiome in CKD patients is significantly altered, indicating that increased intestinal permeability and production of uremic toxin may occur in the upper small intestine of CKD patients.
DAYTRANA was demonstrated to be effective in the treatment of ADHD in two (2) randomized double-blind, placebo-controlled studies in children aged 6 to 12 years and one (1) randomized, double-blind, placebo-controlled study in adolescents aged 13 to 17 years who met Diagnostic and Statistical Manual (DSM-IV-TR®) criteria for ADHD. DAYTRANA wear time was 9 hours in all three (3) studies.

In Study 1, conducted in a classroom setting, symptoms of ADHD were evaluated by school teachers and observers using the Deportment Subscale from the Swanson, Kotkin, Agler, M-Flynn, and Pelham (SKAMP) rating scale which assesses behavior symptoms in the classroom setting. DAYTRANA was applied for 9 hours before removal. There was a 5-week open-label DAYTRANA dose optimization phase using dosages of 10, 15, 20, and 30 mg / 9 hours, followed by a 2-week randomized, double-blind, placebo-controlled crossover treatment phase using the optimal transdermal system dose for each patient or placebo. The mean differences between DAYTRANA and placebo in change from baseline in SKAMP Deportment Scores were statistically significant in favor of DAYTRANA beginning at 2 hours and remained statistically significant at all subsequent measured time points through 12 hours after application of DAYTRANA.

In Study 2, conducted in the outpatient setting, DAYTRANA or placebo was blindly administered in a flexible-dose design using doses of 10, 15, 20, and 30 mg / 9 hours to achieve an optimal regimen over 5 weeks, followed by a 2-week maintenance period using the optimal transdermal system dose for each patient. Symptoms of ADHD were evaluated by the ADHD-Rating Scale (RS)-IV. DAYTRANA was statistically significantly superior to placebo as measured by the mean change from baseline for the ADHD-RS-IV total score. Although this study was not designed specifically to evaluate dose response, in general there did not appear to be any additional effectiveness accomplished by increasing the transdermal system dose from 20 mg / 9 hours to 30 mg / 9 hours.

In Study 3, conducted in the outpatient setting, DAYTRANA or placebo was blindly administered in a flexible-dose design using doses of 10, 15, 20, and 30 mg / 9 hours during a 5-week dose-optimization phase, followed by a 2-week maintenance period using the optimal transdermal system dose for each patient. Symptoms of ADHD were evaluated using the ADHD-Rating Scale (RS)-IV. DAYTRANA was statistically significantly superior to placebo as measured by the mean change from baseline in the ADHD-RS-IV total score.
Angelman syndrome (AS) is a neurodevelopmental disorder caused by abnormal expression of the maternal ubiquitin protein ligase E3A gene (UBE3A). As one of the most challenging symptoms and important focuses of new treatment, sleep disturbance is reported to occur in 70-80% of patients with AS and has a serious impact on the lives of patients and their families. Although clinical studies and animal model studies have provided some clues, recent research into sleep disorders in the context of AS is still very limited. It is generally accepted that there is an interaction between neurodevelopment and sleep; however, there is no recognized mechanism for sleep disorders in AS patients. Accordingly, there are no aetiologically specific clinical treatments for AS-related sleep disorders. The most common approaches involve ameliorating symptoms through methods such as behavioural therapy and symptomatic pharmacotherapy. In recent years, preclinical and clinical studies on the targeted treatment of AS have emerged. Although precision therapy for restoring the UBE3A level and the function of its signalling pathways is inevitably hindered by many remaining obstacles, this approach has the potential to address AS-related sleep disturbance.
The use of inhibitors (I) of enzyme(s) selected from dipeptidyl peptidase IV (DP IV), alanyl-aminopeptidase (aminopeptidase N: APN) and/or enzymes of the same substrate specificities is claimed for reducing neurodegenerative lesions caused by the formation of aggregates of misfolded proteins (e.g. neurofibrillar tangles (NFT)) and blocking or modulating inflammation caused by such lesions, is new. Independent claims are included for: (1) corresponding therapeutic or prophylactic methods using (I); and (2) pharmaceutical preparations (not restricted to particular activities or applications) containing (I) in combination with conventional carriers, additives and/or auxiliaries. ACTIVITY : Neuroprotective; Antiinflammatory; Nootropic; Antiparkinsonian; Anticonvulsant; Antibacterial. Tests were carried out in transgenic mice expressing the human microtubuli-associated tau protein with the P301L mutation under the control of the mouse prion promoter, which develop age-dependent NFT, neurodegeneration and movement deficiency and are a good model for tauopathy in humans (see Nat. Genet., 2000, 25(4), 4020405). Intraperitoneal administration of combinations of DP IV inhibitors (I-49) and APN inhibitors (bestatin hydrochloride, actinonin) at doses of 5-10 mg/kg or the individual inhibitors at 50 mg/kg every 2 to 3 days significantly reduced the number of NFT in both the entorhinal cortex of one hemisphere and the hippocampus of the contralateral area (no quantitative results given), the reduction being greater using a combination of the two types of enzyme inhibitors. MECHANISM OF ACTION : Dipeptidyl peptidase IV (DP IV) inhibitor; alanyl-aminopeptidase (aminopeptidase N: APN) inhibitor.
The participant will undergo the procedure under general anaesthesia. A small amount of fat (20-120 cc) will be harvested using liposuction, from the abdomen or the thighs. Randomized allocation will be made and when allocated to the intervention group, the fat will be purified using decanting and injected into the painful areas of skin.
Object: to provide a novel type of hair growth promoter which has a remarkable action of promoting hair growth and little irritates the skin. Consitution: a hair growth promoter containing an alkanamidoammonium compound represented by general formula (I) as the active ingredient, wherein R?1 represents C7? to C25? alkyl; R?2, R?3 and R?4 may be the same or different from one another and each represents C1? to C4? alkyl; m represents an integer of 2 to 4; and X represents an atom or atomic group acting as an anion.